Anacetrapib
Jump to navigation
Jump to search
Template:Chembox Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease.[1] In 2017 its development was abandoned by Merck.[2]
Evidence
In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.[3]
See also
Other CETP inhibitors:Script error: No such module "Unsubst".
- Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases in blood pressure and had net cardiovascular detriment.
- Dalcetrapib was developed by Hoffmann–La Roche until May 2012. It did not raise blood pressure and did raise HDL, but it showed no clinically meaningful efficacy.
- Evacetrapib was developed by Eli Lilly and Company until October 2015.
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
Further reading
- <templatestyles src="Citation/styles.css"/>Template:Citation/make link, Miller, Ross A. & Cote, Aaron S., "Process for synthesizing a CETP inhibitor", published Script error: No such module "auto date formatter"., assigned to Merck & Co. Inc.Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox".